STOK — Stoke Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.51bn
- $1.27bn
- $36.56m
- 77
- 27
- 88
- 71
Annual income statement for Stoke Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 12.4 | 8.78 | 36.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 53 | 86.1 | 117 | 124 | 138 |
| Operating Profit | -53 | -86.1 | -104 | -115 | -101 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -52.2 | -85.8 | -101 | -105 | -89 |
| Net Income After Taxes | -52.2 | -85.8 | -101 | -105 | -89 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -52.2 | -85.8 | -101 | -105 | -89 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52.2 | -85.8 | -101 | -105 | -89 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.56 | -2.34 | -2.6 | -2.38 | -1.65 |